The estimated Net Worth of Mark S Shearman is at least $337 mil dollars as of 13 February 2023. Dr Shearman owns over 2,790 units of Editas Medicine Inc stock worth over $247,813 and over the last 9 years he sold EDIT stock worth over $88,788.
Dr has made over 4 trades of the Editas Medicine Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he sold 2,790 units of EDIT stock worth $26,979 on 13 February 2023.
The largest trade he's ever made was selling 5,145 units of Editas Medicine Inc stock on 15 June 2022 worth over $51,759. On average, Dr trades about 820 units every 137 days since 2015. As of 13 February 2023 he still owns at least 65,559 units of Editas Medicine Inc stock.
You can see the complete history of Dr Shearman stock trades at the bottom of the page.
Dr. Mark S. Shearman is the Exec. VP & Chief Scientific Officer at Editas Medicine Inc.
Dr Shearman is 61, he's been the Exec. VP & Chief Scientific Officer of Editas Medicine Inc since . There are 7 older and 10 younger executives at Editas Medicine Inc. The oldest executive at Editas Medicine Inc is Dr. George McDonald Church Ph.D., 67, who is the Co-Founder & Scientific Advisory Board Member.
Mark's mailing address filed with the SEC is C/O EDITAS MEDICINE, INC., 11 HURLEY ST., CAMBRIDGE, MA, 02141.
Over the last 9 years, insiders at Editas Medicine Inc have traded over $73,429,036 worth of Editas Medicine Inc stock and bought 241,700 units worth $4,697,822 . The most active insiders traders include Andrew A. F. Hack, Kevin P Starr, eKevin Bitterman. On average, Editas Medicine Inc executives and independent directors trade stock every 22 days with the average trade being worth of $126,770. The most recent stock trade was executed by Baisong Mei on 4 September 2024, trading 518 units of EDIT stock currently worth $1,772.
unlocking the promise of genome editing to deliver life-changing medicines. editas medicine's mission is to translate its genome editing technology into a novel class of human therapeutics that enable precise and corrective molecular modification to treat the underlying cause of a broad range of diseases at the genetic level.
Editas Medicine Inc executives and other stock owners filed with the SEC include: